⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20323928 | 0.84 | PIK3CD (0.33) | — | |
| SCHEMBL27367369 | 0.84 | PIK3CD (0.33) | — | |
| SCHEMBL19157002 | 0.82 | — | — | |
| SCHEMBL15241334 | 0.78 | PIK3CD (0.40) | — | |
| SCHEMBL19314037 | 0.78 | — | — | |
| SCHEMBL19360381 | 0.75 | — | — | |
| SCHEMBL259497 | 0.73 | PIK3CD (0.62) | — | |
| SCHEMBL174185 | 0.73 | — | — | |
| SCHEMBL23152937 | 0.71 | — | — | |
| Hydrochloric Acid SCHEMBL4659475 | 0.71 | PIK3CD (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814373-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230312539-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-10-05 | — | — | US | disclosed |
| US-11731981-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2023-08-22 | — | — | US | disclosed |
| EP-3971182-A1 | 2-SUBSTITUTED AMINO-NAPHTH[1,2-D]IMIDAZOL-5-ONE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | PTC Therapeutics, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| US-20220002310-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2022-01-06 | — | — | US | disclosed |
| WO-2021219731-A2 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-11-04 | — | — | WO | disclosed |
| WO-2021178485-A1 | PYRIMIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USES | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2021-09-10 | — | — | WO | disclosed |
| US-11046706-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2021-06-29 | — | — | US | disclosed |
| US-20190300541-A1 | CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2019-10-03 | — | — | US | disclosed |
| EP-3502099-A1 | CYCLIC COMPOUND ACTING AS PDE4 INHIBITOR | Medshine Discovery Inc. (CN) | 2019-06-26 | — | — | EP | disclosed |
| WO-2018093957-A1 | 2-SUBSTITUTED AMINO-NAPHTH[1,2-D]IMIDAZOL-5-ONE COMPOUNDS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF CROSS REFERENCE TO RELATED APPLICATIONS | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2018-05-24 | — | — | WO | disclosed |
| EP-2872514-B1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-2794565-B1 | HEPATITIS B ANTIVIRAL AGENTS | NOVIRA THERAPEUTICS INC (US) | 2017-07-26 | — | — | EP | disclosed |
| US-9670222-B2 | CCR2 receptor antagonists and uses thereof | CENTREXION THERAPEUTICS CORPORATION (US) | 2017-06-06 | — | — | US | disclosed |
| WO-2017070137-A1 | COMBINATION OF CK2 INHIBITORS AND IMMUNE CHECKPOINT MODULATORS FOR CANCER TREATMENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-27 | — | — | WO | disclosed |
| WO-2013036679-A1 | COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS | SATORI PHARMACEUTICALS, INC. (US) | 2013-03-14 | — | — | WO | disclosed |